Does Blue Cross Blue Shield of North Carolina Cover Forteo?

BCBSNC Formulary Placement for Forteo

Forteo (teriparatide) sits on the BCBSNC specialty tier formulary, which means it carries higher cost-sharing than standard generic medications but remains accessible through the plan's specialty pharmacy pathway. Most BCBSNC commercial plans place teriparatide on Tier 4 or Tier 5, depending on whether the member holds a standard PPO, an HMO product, or enrollment through the North Carolina State Health Plan.

The distinction matters financially. Tier 4 placement typically means a fixed copay between $100 and $200 per 28-day pen supply, while Tier 5 (specialty coinsurance) can mean 20% to 33% of the drug's wholesale acquisition cost. Brand-name Forteo carries a list price near $3,900 for a 28-day pen [1]. The FDA-approved teriparatide biosimilar (Teriparatide-teva, approved November 2023) may sit on a lower specialty tier with some BCBSNC plans, reducing out-of-pocket burden by 15% to 40% compared to brand Forteo.

BCBSNC updates its formulary quarterly. Members should verify current tier placement through the online formulary search tool or by calling the number on the back of their insurance card. The North Carolina State Health Plan (covering state employees, teachers, and retirees) maintains a separate formulary with its own tier structure, though Forteo remains covered under both [2].

Prior Authorization Requirements

BCBSNC requires prior authorization for all teriparatide prescriptions. The request must demonstrate medical necessity based on specific clinical criteria that align closely with the 2020 Endocrine Society Clinical Practice Guideline for osteoporosis management [3].

To gain approval, the prescribing physician must document all of the following: a confirmed diagnosis of osteoporosis via dual-energy X-ray absorptiometry (DXA) with a T-score of -2.5 or below at the hip or spine, OR a history of fragility fracture; failure of, intolerance to, or contraindication to at least one oral bisphosphonate (alendronate or risedronate) used for a minimum of 12 months; and the prescriber must be an endocrinologist, rheumatologist, or orthopedic specialist (though primary care physicians can submit with supporting specialist consultation notes).

BCBSNC also requires documentation that the patient does not have active hypercalcemia, unexplained elevation of alkaline phosphatase, prior radiation therapy to the skeleton, open epiphyses, or pre-existing hypercalcemia. These align with FDA contraindications listed in the Forteo prescribing information [4]. The boxed warning regarding osteosarcoma risk in rats (observed at doses 3 to 58 times the human dose) does not prevent coverage but limits the approved treatment duration to 24 months cumulative lifetime exposure.

Step Therapy: What You Must Try First

BCBSNC enforces step therapy for Forteo. This is not optional. The plan requires documented trial and failure of first-line oral bisphosphonate therapy before approving an anabolic agent.

Acceptable first-line agents include alendronate (Fosamax) 70 mg weekly or risedronate (Actonel) 35 mg weekly, used for at least 12 months with documented adherence. "Failure" can mean continued bone loss on DXA (defined as a statistically significant decrease in BMD beyond the least significant change), new fragility fracture while on therapy, or documented intolerance (e.g., esophagitis, severe GI symptoms confirmed by endoscopy or clinical documentation) [5].

Contraindication to oral bisphosphonates also satisfies step therapy. Accepted contraindications include esophageal disorders (stricture, achalasia, Barrett's esophagus), inability to remain upright for 30 minutes, creatinine clearance <35 mL/min, or documented hypersensitivity.

Patients who present with very high fracture risk (defined by the 2020 Endocrine Society guideline as T-score <-3.0, recent vertebral fractures, or FRAX-calculated 10-year major osteoporotic fracture probability exceeding 30%) may qualify for step therapy override. The prescriber must explicitly cite the guideline recommendation that anabolic therapy should be considered as initial treatment in very high-risk patients [3].

How to Submit a Prior Authorization Request

The prior authorization process for Forteo through BCBSNC follows a standardized pathway. Prescribers can submit electronically through the CoverMyMeds platform, by fax using the BCBSNC prior authorization request form, or by phone to the pharmacy management department.

Required documentation includes: the most recent DXA scan report (within 24 months), clinical notes describing bisphosphonate trial history and outcomes, FRAX score calculation if applicable, relevant lab values (serum calcium, 25-hydroxyvitamin D, alkaline phosphatase, renal function), and the specific ICD-10 diagnosis code (M80.x for osteoporosis with fracture, M81.0 for age-related osteoporosis without fracture).

Standard review takes 5 to 15 business days. Urgent or expedited review (available when delay could cause serious harm) takes 24 to 72 hours. BCBSNC must notify the member and prescriber in writing of approval or denial. Approval is typically granted for 12 months, renewable for a second 12-month period (24 months total maximum per FDA labeling) [4].

Dr. Felicia Cosman, former president of the National Osteoporosis Foundation, has stated: "For patients with very high fracture risk, starting with anabolic therapy followed by an antiresorptive represents the optimal treatment sequence based on current evidence" [6]. This clinical perspective supports the case for initial Forteo use in appropriate patients when submitting prior authorization.

Cost Breakdown: What Members Actually Pay

The out-of-pocket cost for Forteo under BCBSNC depends on the specific plan design, deductible status, and whether the member has reached their out-of-pocket maximum.

For commercial PPO plans with specialty tier coinsurance: members typically pay 25% to 33% of the negotiated rate after deductible. With a negotiated rate around $2,800 to $3,200 per pen (lower than list price due to BCBSNC's pharmacy benefit manager contracts), this translates to roughly $700 to $1,050 per month before any manufacturer assistance. For plans with fixed specialty copays: $150 to $300 per fill is common.

The North Carolina State Health Plan uses a different cost-sharing structure. Under the 80/20 Plan, specialty medications carry a $100 to $250 copay per 30-day supply after deductible. The High Deductible Health Plan (HDHP) requires members to meet the full deductible ($2,000 individual / $4,000 family for 2025-2026) before the plan pays, after which coinsurance applies [7].

Lilly's Forteo Savings Card can reduce commercial copays to as low as $4 per month for eligible commercially insured patients, with a maximum annual benefit of $7,200. This card does not apply to government-funded insurance (Medicare, Medicaid, TRICARE). The biosimilar teriparatide option may offer 15% to 40% lower cost-sharing depending on BCBSNC's negotiated pricing.

According to a 2022 analysis in the Journal of Managed Care & Specialty Pharmacy, average out-of-pocket costs for teriparatide among commercially insured patients were $148 per month after accounting for manufacturer copay assistance programs [8].

North Carolina State Health Plan Specifics

The North Carolina State Health Plan, administered by BCBSNC, covers approximately 740,000 members including active state employees, teachers, university staff, and retirees. Forteo coverage under the State Health Plan follows the same clinical criteria as commercial BCBSNC products but uses a distinct formulary managed by the State Health Plan's Pharmacy and Therapeutics Committee.

Key differences for State Health Plan members include: mandatory use of the plan's designated specialty pharmacy (currently CVS Specialty or Accredo, depending on the contract year), a separate prior authorization form specific to the State Health Plan, and potential access to the State Health Plan's specialty drug assistance program, which caps catastrophic specialty drug costs at a lower threshold than most commercial plans.

State Health Plan retirees enrolled in the Medicare Advantage plan administered by BCBSNC follow Medicare Part D coverage rules for Forteo, which include a coverage gap ("donut hole") phase where members pay 25% of the drug cost until reaching catastrophic coverage [9].

What Happens If Your Claim Is Denied

Denial is not the end. BCBSNC provides a structured appeals process with multiple levels of review, and denial rates for osteoporosis anabolic agents are not uncommon given the step therapy requirements.

Common denial reasons include: insufficient documentation of bisphosphonate failure, DXA scan older than 24 months, missing lab values, or the prescriber not meeting specialty requirements. Most of these are correctable documentation issues rather than true medical necessity failures.

The appeals timeline works as follows. First-level appeal: submit within 180 days of denial, reviewed by a physician reviewer not involved in the original decision, decision within 30 calendar days. Second-level appeal (external review): available if first-level appeal is denied, conducted by an independent review organization (IRO) under North Carolina Department of Insurance oversight, decision within 45 days. North Carolina General Statute § 58-50-75 through § 58-50-95 governs the external review process and provides strong consumer protections [10].

Effective appeal letters should include: an updated letter of medical necessity from the prescriber citing specific guideline recommendations, the patient's complete fracture history, a copy of the FRAX assessment, documentation of bisphosphonate trial with specific dates and outcomes, and any supporting peer-reviewed literature. The AACE/ACE 2020 Clinical Practice Guidelines for Diagnosis and Treatment of Postmenopusal Osteoporosis provide strong supporting evidence for anabolic-first approaches in very high-risk patients [11].

Alternatives If Forteo Is Not Covered or Too Expensive

If Forteo coverage proves unattainable or cost-prohibitive even with assistance programs, BCBSNC covers several alternative osteoporosis medications that may be appropriate depending on the clinical scenario.

Denosumab (Prolia) 60 mg subcutaneous every 6 months is covered under the medical benefit (not pharmacy benefit) when administered in-office, which can simplify coverage. Romosozumab (Evenity), another anabolic agent, is covered by BCBSNC with similar prior authorization requirements but works through a different mechanism (sclerostin inhibition). The ARCH trial (N=4,093) demonstrated that romosozumab followed by alendronate reduced vertebral fracture risk by 48% compared to alendronate alone at 24 months [12].

Zoledronic acid (Reclast) 5 mg IV annually represents a potent bisphosphonate option covered under BCBSNC's medical benefit. The HORIZON-PFT trial (N=7,765) showed 70% reduction in vertebral fractures and 41% reduction in hip fractures over 3 years compared to placebo [13]. For patients who failed oral bisphosphonates due to GI intolerance rather than efficacy failure, IV zoledronic acid bypasses the GI tract entirely.

Abaloparatide (Tymlos), a PTHrP analog, is also covered by BCBSNC under specialty tier with prior authorization. The ACTIVE trial (N=2,463) demonstrated 86% reduction in new vertebral fractures compared to placebo at 18 months [14].

Filing a Complaint with the NC Department of Insurance

If all internal appeals are exhausted and the member believes the denial violates North Carolina insurance law, a formal complaint can be filed with the North Carolina Department of Insurance (NCDOI). The NCDOI Consumer Services Division investigates complaints against insurers and can mandate coverage when the denial violates state regulations.

North Carolina has a state-mandated external review law (N.C. Gen. Stat. § 58-50-80) that requires insurers to comply with independent review organization decisions. If the IRO overturns BCBSNC's denial, the plan must authorize coverage within 5 business days. The NCDOI processed over 4,200 health insurance complaints in 2024, with resolution rates favoring consumers in approximately 35% of cases involving medical necessity disputes.

Members can file online through the NCDOI website or by calling 855-408-1212. Required documentation includes copies of all denial letters, appeal submissions, and clinical records submitted during the appeals process.

Maximizing Your Coverage: Practical Steps

Start the prior authorization process before filling the prescription. Ask your physician's office to submit the PA request proactively once the decision to prescribe Forteo has been made. Confirm which specialty pharmacy BCBSNC requires for your specific plan. Enroll in the Lilly Forteo Savings Card program simultaneously so it activates once PA approval comes through.

Request your physician document the FRAX score, specific T-scores at all measured sites, complete fracture history with imaging dates, and the exact bisphosphonate regimen attempted (drug name, dose, start date, end date, reason for discontinuation). The more specific the documentation, the higher the first-pass approval rate.

If denied, do not abandon the process. Request the specific clinical criteria used for denial in writing. BCBSNC must provide this under 45 CFR § 147.136 (federal external review rules applicable to non-grandfathered plans). Address each stated deficiency point-by-point in your appeal. The 2020 Endocrine Society guideline explicitly recommends anabolic therapy as first-line for very high-risk patients, defined as those with T-score ≤ -3.0 at spine or hip, or recent vertebral fracture within 12 months [3].